The crypto rollercoaster continues! 🎢 #AKRO is feeling the squeeze, dropping 10.57% to $0.000981, while #VIDT is practically in freefall at a staggering 93.1% lower to ₿0.00000002! 🤯 #FOR tumbles 16.85% to $0.00306. Tough times ahead! Stay sharp! #Crypto

Investor Rights Firm Urges Shareholders of WOW, AKRO, HFWA, and BRY to Speak Up About Their Options Halper Sadeh LLC is investigating companies like WOW, AKRO, HFWA, and BRY for potential securities law violations. Shareholders should act swiftly to protect their rights.

Investor Rights Firm Urges Shareholders of WOW, AKRO, HFWA, and BRY to Speak Up About Their Options #USA #New_York #Halper_Sadeh_LLC #WOW #AKRO

Halper Sadeh LLC Calls on NIC, AKRO, BRNS Shareholders to Assert Their Rights Investors of Nicolet Bankshares, Akero Therapeutics, and Barinthus Biotherapeutics are urged to connect with Halper Sadeh LLC to explore their legal rights regarding corporate actions.

Halper Sadeh LLC Calls on NIC, AKRO, BRNS Shareholders to Assert Their Rights #USA #New_York #Halper_Sadeh #AKRO #NIC

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 Akero Therapeutics (NASDAQ: AKRO) presented new analyses from 96-week Phase 2b SYMMETRY and HARMONY trials of efruxifermin at AASLD 2025 (Nov 7-11, 2025). Post-hoc and AI-assisted digital pathology analyses corroborated prior conventional-pathology findings, reporting antifibrotic activity, reductions in total fibrosis and septa area, and statistically significant improvements in noninvasive measures linked to lower risk of liver-related events and clinically significant portal hypertension (CSPH) in compensated cirrhosis (F4c).Four presentations (two oral, two posters) detail these results and timing: SYMMETRY and HARMONY data are being further validated in the company’s ongoing Phase 3 program.

#AKRO Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

www.stocktitan.net/news/AKRO/akero-therapeu...

Halper Sadeh LLC Urges Shareholders of FFWM, AKRO, CCRD to Assert Their Rights Promptly As a leading investor rights law firm, Halper Sadeh LLC invites shareholders of FFWM, AKRO, and CCRD to discuss their legal rights regarding ongoing investigations.

Halper Sadeh LLC Urges Shareholders of FFWM, AKRO, CCRD to Assert Their Rights Promptly #United_States #New_York #Halper_Sadeh #FFWM #AKRO

What a rocky ride in crypto land! 📉 #BCH is tumbling down 25.24% to $322, while #AKRO isn't faring much better, slipping 10.57% to $0.000981. On a brighter note, #PHAB has rebounded 10.12% to $0.1034 and #ZKC climbed 10.97% to $0.2448. Time to stay sharp! 💡

Yikes! The crypto tide is turning dark! 🌩️ #WTC is tumbling 56.54% to just $0.0103, and #HIFI isn't faring much better, down 21.31% at $0.127. #PERL and #AKRO are also feeling the heat with -20.55% and -10.57%. Time to reassess those portfolios! #Crypto

#ETNB and today #AKRO both aquired, now only #VKTX left.
Long

CNBC: Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion

#NVO = -2%

#AKRO = +20%

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion Akero Therapeutics, Inc. (“Akero”) (Nasdaq: AKRO), a clinical-stage

#AKRO Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion

www.stocktitan.net/news/AKRO/akero-therapeu...

The market's throwing some heavy punches today! 😬 #OGN is taking the spotlight with a jaw-dropping rise of 44.56% to $0.1129! Meanwhile, #AKRO and #STGB are stumbling, down over 10%. What a rollercoaster ride! Who's holding on tight? 🎢 #Crypto

What a rollercoaster! 🎢 #BALBUSD has taken a hit, down 10.97% at $3.15. #FIRO is stumbling hard, down 25% to $0.30. #AKRO is feeling the pressure at $0.000981, down 10.57%. #BURGER is crumbling, having dropped 28.63% to $0.0172 and #QI is down 29.41%! Time to stay sharp, folks! ⚡️#Crypto

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Akero Therapeutics (Nasdaq: AKRO) reported significant progress in its clinical programs for EFX, a potential first- and best-in-class therapy for MASH (Metabolic dysfunction-Associated SteatoHepatitis). The company's 96-Week Phase 2b SYMMETRY trial results were published in the New England Journal of Medicine, demonstrating statistically significant reversal of compensated cirrhosis in MASH patients.At EASL 2025, three presentations highlighted EFX's anti-fibrotic activity across all MASH stages. The data showed promising results in high-risk patient subgroups, including those with cryptogenic cirrhosis and type 2 diabetes. New analyses from the HARMONY study confirmed consistent fibrosis improvement in pre-cirrhotic MASH patients using both conventional and AI-based analysis methods.Financially, Akero reported $1.09 billion in cash and equivalents as of June 30, 2025, expected to fund operations into 2028. Q2 operating expenses increased to $80.9 million, up from $65.7 million in the previous year, primarily due to ongoing Phase 3 trials.

#AKRO Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/AKRO/akero-therapeu...

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Akero Therapeutics (NASDAQ: AKRO) reported significant Q1 2025 results, highlighted by groundbreaking Phase 2b SYMMETRY study outcomes showing statistically significant reversal of cirrhosis in MASH patients after 96 weeks of efruxifermin (EFX) treatment. Key findings include 39% of patients in the 50mg EFX group showing ≥1-stage fibrosis improvement, representing a 24% effect size over placebo. The company strengthened its financial position with a $402.5M follow-on offering, ending Q1 with $1.13B in cash reserves. Operating expenses increased to $80.9M, up from $60.0M in Q1 2024. The Phase 3 SYNCHRONY program continues to advance, with preliminary results from Real-World study expected in H1 2026. The SYMMETRY results were published in the New England Journal of Medicine and presented at EASL 2025, highlighting EFX's potential as a first- and best-in-class therapy for MASH treatment.

#AKRO Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/AKRO/akero-therapeu...

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 Akero Therapeutics (NASDAQ: AKRO) presented new analyses of their Phase 2b HARMONY trial for efruxifermin (EFX) in pre-cirrhotic MASH patients at EASL Congress 2025. The study utilized HistoIndex's AI-based qFibrosis® digital pathology analysis alongside conventional methods. Key findings showed that among patients treated with 50mg EFX, over 50% were classified as responders across all three endpoints (qFibrosis®, ELF test score, and FibroScan®), compared to less than 5% in the placebo group. At Week 96, the 50mg EFX group (N=26) showed similar response rates between conventional pathology (77%) and qFibrosis® (81%). Notably, qFibrosis® detected more responders at Week 24 (18 patients) compared to conventional pathology (10 patients), suggesting earlier detection of treatment response.

#AKRO Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

www.stocktitan.net/news/AKRO/akero-therapeu...

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine Akero Therapeutics (NASDAQ: AKRO) announced the publication of its Phase 2b SYMMETRY trial results in the New England Journal of Medicine, evaluating efruxifermin (EFX) for treating compensated cirrhosis due to MASH. The 96-week study showed significant fibrosis improvement, with 29% of participants in the EFX 50mg group and 21% in the 28mg group showing improvement compared to 11% in the placebo group.At week 36, the primary endpoint of ≥1-stage fibrosis improvement without MASH worsening was achieved by 19% and 18% of participants in the 50mg and 28mg groups respectively, versus 13% for placebo. The treatment demonstrated improvements in liver injury markers, insulin sensitivity, and lipid metabolism. Safety profile was consistent with previous trials, with mainly mild to moderate gastrointestinal side effects.

#AKRO Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

www.stocktitan.net/news/AKRO/akero-therapeu...

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025 Akero Therapeutics has announced multiple presentations at the upcoming EASL Congress 2025 in Amsterdam, showcasing research on their drug efruxifermin for treating metabolic diseases. The company will present two oral presentations and one poster focusing on liver disease treatment. The first oral presentation by Dr. Mazen Noureddin will discuss efruxifermin's impact on fibrosis improvement in patients with compensated cirrhosis due to MASH, based on a 96-week Phase 2b trial (SYMMETRY). The second oral presentation by Prof. Quentin M. Anstee will explore the alignment of non-invasive fibrosis biomarkers with AI-based qFibrosis histology in MASH trials. Additionally, a poster presentation by Prof. Jörn M. Schattenberg will demonstrate how qFibrosis enables earlier detection of fibrosis response in efruxifermin-treated patients with F2-F3 MASH in the 96-week HARMONY study. All presentations will take place between May 7-10, 2025.

#AKRO Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

www.stocktitan.net/news/AKRO/akero-therapeu...

I've been waiting for this, coming back to #VRCHAT soon.....
.
.
.
.
.
#virtualreality
#akro
#akromod

Can Akero's Breakthrough Cirrhosis Reversal Results Reshape MASH Treatment Landscape? 39% of patients showed fibrosis improvement with efruxifermin. Strong $1.2B cash position extends runway into 2028 as Phase 3 enrollment completes.

#AKRO Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/AKRO/akero-therapeu...

Akero's Massive $350M Capital Raise Signals Major Development Push in NASH Treatment Akero Therapeutics prices upsized offering at $48.00 per share, including 5.3M shares and pre-funded warrants, backed by major banks. Closing expected January 30.

#AKRO Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/AKRO/akero-therapeu...

#MDGL has already closed the gap from yday's home-run data by #AKRO . There's plenty of room for multiple drugs for #MASH , and as good as EFX' Ph2b results look, it's gonna be a couple of years b4 it gets to market, and by the MDGL will almost certainly exist under a different ticker.

Akero Therapeutics Announces $300M Public Stock Offering to Advance Metabolic Disease Pipeline Clinical-stage biotech Akero Therapeutics launches major public offering with top-tier underwriters JP Morgan, Morgan Stanley, and Jefferies backing the $300M raise.

#AKRO Akero Therapeutics Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/AKRO/akero-therapeu...

BREAKING NEWS: ( NASDAQ: #AKRO ) Why did Akero (AKRO) stock soar 110% on Monday?

Just In: ( NASDAQ: #AKRO ) Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH-by Both Completer and ITT Analyses-at Week 96 in Phase 2b SYMMETRY Study

Old Style Random Thoughts Update Been a long week so far today

Forgot to link article this a.m. so you get the new and improved version 😅 filzucchi.substack.com/p/old-style-... #SPY #QQQ #CEG #GEV #QCOM #MU #AKRO #MDGL #NVDA #PRIM #VRT

2/ If not stat sig, but showing improvement consistent w/36w results, I'll stick my neck out that #AKRO Stk reaction won't be anything like Oct'23. Either way, imo this data will be very telling for the whole program, and how EFX may ultimately compete w/ #MDGL #ETNB

1/ The Oct '23 36w readout of EFX Ph2b crushed #AKRO stk despite what looked like pretty impressive data given the short time to readout & the tough pts pop it's tackling. The 96w readout is coming in Feb. If stat sign - despite study not being powered for that - stk cud/shud fly... #ETNB #MDGL